Sinus Lift Associated with Leucocyte-Platelet-Rich Fibrin (Second Generation) for Bone Gain: A Systematic Review

Abstract

The purpose of this systematic review was to analyze sinus lifting procedures and to compare the efficiency of this treatment associated with the second generation of platelet-rich fibrin related to its effects on bone gain and to clarify the regenerative efficacy in sinus lift procedure, whether alone or as a coadjutant to other bone graft materials. The PICOT question was, “In clinical studies with patients needing a maxillary sinus lift (P), does the use of PRF either alone (I) or in conjunction with other biomaterials (C) improve the clinical outcome associated with bone gain and density (O), with at least three months of follow-up (T)?” An electronic search was conducted in the MEDLINE (PubMed), Science Direct, and Scopus databases through a search strategy. A total of 443 articles were obtained from the electronic database search. Sixteen articles met all criteria and were included in this review. Within the limitation of this study and interpreting the results carefully, it was suggested that a higher risk for implant failure after a sinus elevation might be seen in patients with residual bone ≤4 mm, and PRF application was effective, suggesting reducing the time needed for new bone formation.

Autologous leucocyte and platelet rich in fibrin (L-PRF) – is it a competitive solution for bone augmentation in maxillary sinus lift? A 6-month radiological comparison between xenografts and L-PRF

“…Our study included more patients who benefitted from the external sinus lift with xenograft materials than implants and L-PRF alone as the sole biomaterial. Although, in the last decade, many studies have been published on the sinus augmentation topic, where the grafting material used was combined with platelet-rich in fibrin concentrate [ 40 – 44 ], fewer exist that used only L-PRF as a single grafting material [ 45 , 46 ]. For example, the study of Dominiak compared two small groups of patients - only 30 implants in total, xenograft versus PRF, ensuring a 3 year retrospective, but only panoramic evaluation, not CBCT [ 47 ].…”

Critical‐size defects reconstruction with four different bone grafts associated with e‐PTFE membrane: A histomorphometric experimental in vivo study

“…In attempting to reduce these problems, several alternative biomaterials have been developed. Bone harvested from animals (heterogenous/xenograft biomaterial), especially bovine, has gained popularity (Harduin‐Couto et al., 2022; Monteiro et al., 2022; Otero et al., 2022). Otherwise, this biomaterial only possesses osteoconductive properties (Artzi et al., 2001), and even though it has satisfactory effectiveness, safety, and a high success rate, it presents a low reabsorption rate (Fernández et al., 2017).…”

“…In attempting to reduce these problems, several alternative biomaterials have been developed. Bone harvested from animals (heterogenous/xenograft biomaterial), especially bovine, has gained popularity (Harduin-Couto et al, 2022;Monteiro et al, 2022;Otero et al, 2022).…”

J Clin Exp Dent

“…Since then, lateral sinus floor elevation has become a standard surgical procedure for bone augmentation. A variety of materials have been employed for this purpose, including autogenous bone ( 1 , 2 ), allogenic bone ( 3 ), synthetic materials ( 4 , 5 ), recombinant human bone morphogenetic protein-2 delivered on a collagen sponge (BMP-2/collagen) ( 6 ), and autogenous blood-derived materials ( 7 , 8 ). Clinical studies on the BMP-2/collagen device have shown successful bone augmentation, as well as short-term safety and technical feasibility within 16 weeks ( 6 ).…”

“…Clinical studies on the BMP-2/collagen device have shown successful bone augmentation, as well as short-term safety and technical feasibility within 16 weeks ( 6 ). Blood-derived materials which contain thick fibrin fibers with platelets have also been explored ( 7 , 8 ). Animal studies have suggested that the demineralized dentin matrix (DDM) possesses bone-inductive abilities ( 9 , 10 ).…”